

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW  
1100 NEW YORK AVENUE, N.W., SUITE 600  
WASHINGTON, D.C. 20005-3934

www.skgf.com

PHONE. (202) 371-2600 FACSIMILE (202) 371-2540

ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. ESMOND  
TRACY-GENE G. DURKIN  
MICHAEL A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOHL  
ERIC K. STEFFE  
MICHAEL O. LEE

STEVEN R. LUDWIG  
JOHN M. COVERT\*  
LINDA E. ALCORN  
RAZ E. FLESHNER  
ROBERT C. MILLONIG  
MICHAEL V. MESSINGER  
JUDITH U. KIM  
TIMOTHY J. SHEA, JR.  
DONALD R. MCPHAIL  
PATRICK E. GARRETT  
STEPHEN G. WHITESIDE  
JEFFREY T. HELVEY\*

HEIDI L. KRAUS  
JEFFREY R. KURIN  
RAYMOND MILLIEN  
PATRICK D. O'BRIEN  
LAWRENCE B. BUGAISKY  
CRYSTAL D. SAYLES\*  
EDWARD W. YEE  
ALBERT L. FERRO\*  
DONALD R. BANOWIT  
PETER A. JACKMAN  
MOLLY A. MCCALL  
TERESA U. MEDLER

JEFFREY S. WEAVER  
KRISTIN K. VIDOVICH  
KENDRICK P. PATTERSON  
DONALD J. FEATHERSTONE  
GRANT E. REED  
VINCENT L. CAPUANO  
JOHN A. HARROUN\*  
MATTHEW M. CATLETT\*  
NATHAN K. KELLEY\*  
ALBERT J. FASULO II\*  
W. BRIAN EDGE\*

KAREN R. MARKOWICZ\*\*  
SUZANNE E. ZISKA\*\*  
BRIAN J. DEL BUONO\*\*  
ANDREA J. KAMAGET\*\*  
NANCY J. LEITH\*\*  
TARJA H. NAUKKARINEN\*\*

\*BAR OTHER THAN D.C.  
\*\*REGISTERED PATENT AGENTS

July 21, 2000

WRITER'S DIRECT NUMBER: (202) 371-2626

INTERNET ADDRESS: SLUDWIG@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

Box: Patent Application

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)  
Appl. No. To be assigned; Filed: July 21, 2000  
For: **Methods for Producing L-Amino Acids**  
Inventors: O'Donohue *et al.*  
Our Ref: 1533.1010002/SRL/CMB

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.  
Patent and Trademark Office:

1. PTO Fee Transmittal (Form PTO/SB/17) (in duplicate);
2. PTO Utility Patent Application Transmittal (Form PTO/SB/05);
3. U.S. Utility Patent Application entitled:

Methods for Producing L-Amino Acids

and naming as inventors:

Michael R. O'Donohue, and  
Paul D. Hanke

Commissioner for Patents

July 21, 2000

Page 2

the application consisting of:

1. A specification containing:
  - i. 32 pages of description prior to the claims;
  - ii. 3 pages of claims (Claims 1-23);
  - iii. a one (1) page abstract;
  - iv. 3 sheets of Formal Drawings (Figures 1A, 1B, and 1C), approval of which is respectfully requested;
  - v. Paper copy of the Sequence Listing;
4. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate);
5. Statement Regarding Sequence Listing;
6. Computer readable copy of the Sequence Listing;
7. Information Disclosure Statement;
8. Form PTO-1449 (3 pages);
9. Copies of references AR1, AS1, AT1, AR2, AS2, AT2, AR3, AS3 and AT3;
10. Our check No. 28166 for \$ 822.00 to cover:

\$ 690.00	Filing fee for patent application; and
\$ 132.00	Fee for excess claims; and
11. Two return postcards.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be

Commissioner for Patents


July 21, 2000

Page 3

stamped with the filing date and unofficial application number and returned as soon as possible. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Steven R. Ludwig  
Attorney for Applicants  
Registration No. 36,203

P:\USERS\Cbouchez\1533\1010002\1533101-2.cvr  
SKGF Rev. 5/30/00 mac



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.	1533.1010002/SRL/CMB
First Inventor or Application Identifier	Michael R. O'Donohue
Title	Methods for Producing L-Amino Acids
Express Mail Label No.	

PTO  
10877  
09/24/98  
07/21/00APPLICATION ELEMENTS  
See MPEP chapter 600 concerning utility patent application contentsADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 36 ]  
(preferred arrangement set forth below)  
- Descriptive title of the Invention  
- Cross References to Related Applications  
- Statement Regarding Fed sponsored R & D  
- Reference to Microfiche Appendix  
- Background of the Invention  
- Brief Summary of the Invention  
- Brief Description of the Drawings (if filed)  
- Detailed Description  
- Claim(s)  
- Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 3 ]
4. ☐ Oath or Declaration [Total Pages        ]  
a. ☐ Newly executed (original or copy)  
b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)  
[Note Box 5 below]  
i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4h is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  
a. ☒ Computer Readable Copy  
b. ☒ Paper Copy (identical to computer copy)  
c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ \*Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired  
(PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☒ Other 37 C.F.R. § 1.136(a)(3) Authorization  
☐ Other:

\*NOTE FOR ITEMS 1 &amp; 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No:        /       Prior application information: Examiner                      Group/Art Unit:                     

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number  
or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence  
address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.				
	Attorneys at Law				
ADDRESS	Suite 600, 1100 New York Avenue, N.W.				
CITY	Washington	STATE	DC	ZIP CODE	20005-3934
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX	(202) 371-2540

NAME (Print/Type)	Steven R. Ludwig	Registration No. (Attorney/Agent)	36,203
SIGNATURE		Date	July 21, 2000

ID G6PI MYCTU STANDARD; PRT; 553 AA.  
AC P77895;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 30-MAY-2000 (Rel. 39, Last annotation update)  
DE GLUCOSE-6-PHOSPHATE ISOMERASE (GPI) (EC 5.3.1.9) (PHOSPHOGLUCOSE  
DE ISOMERASE) (PGI) (PHOSPHOHEXOSE ISOMERASE) (PHI).  
GN PGI OR RV0946C OR MTCY10D7.28.  
OS Mycobacterium tuberculosis.  
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;  
OC Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium.  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=H37RV;  
RX MEDLINE; 98295987.  
RA Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D.,  
RA Gordon S.V., Eiglmeier K., Gas S., Barry C.E. III, Tekala F.,  
RA Badcock K., Basham D., Brown D., Chillingworth T., Connor R.,  
RA Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S.,  
RA Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L.,  
RA Oliver S., Osborne J., Quail M.A., Rajandream M.A., Rogers J.,  
RA Rutter S., Seeger K., Skelton S., Squares S., Squires R., Sulston J.E.,  
RA Taylor K., Whitehead S., Barrell B.G.;  
RT "Deciphering the biology of Mycobacterium tuberculosis from the  
RT complete genome sequence";  
RL Nature 393:537-544 (1998).  
CC -!- CATALYTIC ACTIVITY: GLUCOSE 6-PHOSPHATE = FRUCTOSE 6-PHOSPHATE.  
CC -!- PATHWAY: INVOLVED IN GLYCOLYSIS AND IN GLUCONEOGENESIS.  
CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC (BY SIMILARITY).  
CC -!- SIMILARITY: BELONGS TO THE GPI FAMILY.  
-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
-----  
DR EMBL; Z79700; CAB02004.1; -.  
DR TUBERCULIST; RV0946C; -.  
DR INTERPRO; IPR001672; -.  
DR PFAM; PF00342; GPI; 1.  
DR PRINTS; PR00662; G6PIISOMERASE.  
DR PROSITE; PS00765; P\_GLUCOSE\_ISOMERASE\_1; 1.  
DR PROSITE; PS00174; P\_GLUCOSE\_ISOMERASE\_2; 1.  
KW Gluconeogenesis; Glycolysis; Isomerase.  
SQ SEQUENCE 553 AA; 59974 MW; FB57DFFD1638AE4 CRC64;  
MTSAPIPDIT ATPAWDALRR HHDQIGNTHL RQFFADDPGR GRELTVSVDG LYIDYSKHRV  
TRFTALLID LARTAHLEER RDQMAGVHI NTSEDAVLH TALRLPRDAE LVVDGQDVVT  
DVHAVLDAMG AFTDRLRSGE WTGATGKRIS TVVNIIGGGS DLGPVMVYQA LRHYADAGIS  
ARFVSNVDP A DLATLADLD PATTLFIVAS KTFSTLETLT NATAARRWLT DALGDAAVSR  
HFVAVSTNKR LVDDFGINTD NMFGEWDWVG GRYSVDSAIG LSLMTVIGRD AFADFLAGFH  
IIDRHFATAP LESNAPVLLG LIGLWYSNFF GAQSRTVLPY SNDLSREFAY LQQLTMESNG  
KSTRADGSPV SADTGEIFWG EPGTNGQHAF YQLLHQGTRL VPADFIGFAQ PLDDLPTAEG  
TGSMDHLLMS NEFAQTQVLA FGKTAEEIAA DGTFAHVVAH KVMPEGNRPST SILASRLTFS  
VLGQLALYE HQVETEGVVW GIDSDQWGV ELGKTQAKAL LPVITGAGSP PPQSDSSTDG  
LVRRYRTERG RAG

//

## Methods for Producing L-Amino Acids

### *Cross-Reference to Related Applications*

This application is a nonprovisional of U.S. Application No. 60/145,217, filed July 23, 1999 and U.S. Application No. 60/150,017, filed August 20, 1999, both of which contents are incorporated herein by reference.

### *Background of the Invention*

#### *Field of the Invention*

The present invention relates, in general, to a method of producing L-amino acids and to a gene encoding phosphoglucoisomerase.

#### *Background Information*

Bacterial cells are used industrially to produce amino acids by fermentation processes (Ishino, S. *et al.*, *J. Gen. Appl. Microbiol.* 37:157-165 (1991), Kinoshita, S., Nakayama, K. and Nagasaki, S., *J. Gen. Appl. Microbiol.* 4:128-129 (1958)). Although numerous research reports and reviews have appeared concerning fermentation processes and the mechanisms of accumulation of amino acids, more progress needs to be made to increase the yields of amino acids from microorganisms (Ishino, S. *et al.*, *J. Gen. Appl. Microbiol.* 37:157-165 (1991), Aida, K. *et al.*, eds., "Biotechnology of Amino Acid Production," Kodansha (Tokyo)/Elsevier (New York) (1986) and Marx, A. *et al.*, *Metabolic Engineering* 1:35-48 (1999)).

There has been some success in using metabolic engineering to direct the flux of glucose derived carbons toward aromatic amino acid formation (Flores, N. *et al.*, *Nature Biotechnol.* 14:620-623 (1996)). However, the successful application in producer strains has not yet been documented (Berry, A., *TIBTECH* 14:250-256 (1996)).

Metabolic engineering relates to manipulation of the flow of carbons of starting materials, such as carbohydrates and organic acids, through the variety

of metabolic pathways during fermentation. Studies have been done, for example, on the central metabolism of *Corynebacterium glutamicum* using  $^{13}\text{C}$  NMR studies (Ishino, S. *et al.*, *J. Gen. Appl. Microbiol.* 37:157-165 (1991), Marx, A. *et al.*, *Biotechnology and Bioengineering* 49:111-129 (1996)). Additionally, also using  $^{13}\text{C}$  NMR, Walker *et al.* (Walker, T. *et al.*, *J. Biol. Chem.* 257:1189-1195 (1982)) analyzed glutamic acid fermentation by *Microbacterium ammoniaphilum*, and Inbar *et al.* (Inbar, L. *et al.*, *Eur. J. Biochem.* 149:601-607 (1985)) studied lysine fermentation by *Brevibacterium flavum*.

The present invention solves a problem of improving yields of amino acids during fermentation using metabolic engineering.

### ***Summary of the Invention***

The present invention provides a method of producing L-amino acids by culturing altered bacterial cells having increased amounts of NADPH as compared to unaltered bacterial cells, whereby L-amino acid yields from said altered bacterial cells are greater than yields from unaltered bacterial cells.

The present invention also provides a method of producing a bacterial cell with a mutated phosphoglucose isomerase (*pgi*) gene comprising (a) subcloning an internal region of the *pgi* gene into a suicide vector; and (b) inserting said suicide vector into a bacterial genome, via homologous recombination, whereby a bacterial cell with an altered *pgi* gene is produced. The invention further provides an altered bacterial cell produced according to this method.

The invention also provides a vector useful according to this method.

The present invention further provides isolated nucleic acid molecules comprising a polynucleotide encoding the *Corynebacterium glutamicum* phosphoglucose isomerase polypeptide having the amino acid sequence shown in Figure 1 (SEQ ID NO:2) or one of the amino acid sequence encoded by the DNA clone deposited in a bacterial host as NRRL Deposit Number B-30174 on August 17, 1999.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells

containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of Pgi polypeptides or peptides by recombinant techniques.

The invention further provides an isolated Pgi peptide having an amino acid sequence encoded by a polynucleotide described herein.

Further advantages of the present invention will be clear from the description that follows.

### ***Brief Description of the Figures***

**Figure 1A-1C** shows the nucleotide (SEQ ID NO:1) and deduced amino acid (SEQ ID NO:2) sequences of *pgi*. The Pgi peptide has a deduced molecular weight of about 59 KDa.

### ***Detailed Description of the Invention***

It has been determined herein that increased amounts of NADPH in a bacterial cell increase product yield, specifically in anabolic processes where NADPH is a limiting factor. A way of carrying chemical energy from reactions of catabolism to the energy-requiring reactions of biosynthesis, such as the formation of amino acids, is in the form of hydrogen atoms or electrons. To be effective as reducing agents, hydrogen atoms must have considerable free energy. Such high-energy hydrogen atoms are obtained from cell fuels by dehydrogenases, which catalyze removal of hydrogen atoms from fuel molecules and their transfer to specific coenzymes, particularly to the oxidized form of nicotinamide adenine dinucleotide phosphate (NADP<sup>+</sup>). The reduced, or hydrogen-carrying, form of this coenzyme, designated NADPH, is a carrier of energy-rich electrons from catabolic reactions to electron-requiring biosynthetic reactions.

The present invention provides a method for producing L-amino acids by culturing altered bacterial cells having increased amounts of NADPH as



compared to unaltered bacterial cells whereby L-amino acid yields from said altered bacterial cells are greater than yields from unaltered bacterial cells. Preferred amino acids are L-lysine, L-threonine and L-isoleucine. As used herein, an altered bacterial cell is defined as a bacterial cell which has increased amount of NADPH as compared to an unaltered bacterial cell.

In one preferred embodiment, an "altered" bacterial cell is a "mutated" bacterial cell. A "mutation" is any detectable change in the genetic material which can be transmitted to daughter cells. A mutation can be any (or a combination of) detectable, unnatural change affecting the chemical or physical constitution, mutability, replication, phenotypic function, or recombination of one or more deoxyribonucleotides; nucleotides can be added, deleted, substituted for, inverted, or transposed to new positions with and without inversion. Mutations can occur spontaneously and can be induced experimentally by application of mutagens or recombinant DNA technology. A mutant variation of a nucleic acid molecule results from a mutation. A mutant polypeptide can result from a mutant nucleic acid molecule.

Additionally, an altered or mutated bacterial cell can be genetically "mutated" to yield an increased amount of NADPH as compared to the genetically "unmutated" cell.

An increased amount of NADPH in the altered bacterial cell results in increased production of amino acids. Preferably, in an altered bacterial cell, amino acid yields are increased over yields from the unaltered cell from greater than about 1%, and preferably from about 1% to about 100%, preferably from about 2% to about 80%, and more preferably, from about 5% to about 60%, and even more preferably from about 10% to about 80%. As used herein, "yield" is defined as grams of amino acid produced, multiplied by 100, divided by grams of glucose consumed.

In agreement with the present invention, the altered bacterial cell of the present invention is cultured in a culture medium that comprises a carbon source and a nitrogen source. The carbon source can be, for example, arabinose, cellobiose, fructose, glucose, lactose, maltose, mannose, rhamnose, raffinose, sorbose, sucrose, trehalose, pyruvate, or succinate. The carbon source is

preferably at an initial concentration of 0.1 to 10%, preferably 0.5 to 6.0% by weight. All of the carbon source can be added to the medium before the start of culturing, or it can be added step by step or continuously during culturing.

The medium used herein can be solid or liquid, synthetic (*i.e.* man-made) or natural, and contains sufficient nutrients for the cultivation of the altered bacterial cell of the present invention. Preferably, the medium employed is a liquid medium, more preferably a synthetic liquid medium.

The natural or synthetic culture media used in the above and below described embodiments of the invention also contain a nitrogen source, suitable inorganic salts, and, as appropriate, various trace nutrients, growth factors and the like suitable for cultivation of the altered bacterial cell, and can also contain at least one supplementary carbon source. The amount of each of these additional ingredients to be employed is preferably selected to maximize amino acid production. Such amounts can be determined empirically by one skilled in the art according to the various methods and techniques known in the art.

Illustrative examples of suitable supplemental carbon sources include, but are not limited to: other carbohydrates, such as glucose, fructose, sucrose, starch or starch hydrolysate, cellulose hydrolysate and molasses; organic acids, such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid; and alcohols, such as glycerol, inositol, mannitol and sorbitol.

Illustrative examples of suitable nitrogen sources include, but are not limited to: ammonia, including ammonia gas and aqueous ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium nitrate, ammonium phosphate, ammonium sulfate and ammonium acetate; urea; nitrate or nitrite salts, and other nitrogen-containing materials, including amino acids as either pure or crude preparations, meat extract, peptone, fish meal, fish hydrolysate, corn steep liquor, casein hydrolysate, soybean cake hydrolysate, yeast extract, dried yeast, ethanol-yeast distillate, soybean flour, cottonseed meal, and the like.

Illustrative examples of suitable inorganic salts include, but are not limited to: salts of potassium, calcium, sodium, magnesium, manganese, iron,

cobalt, zinc, copper, molybdenum, tungsten and other trace elements, and phosphoric acid.

Illustrative examples of appropriate trace nutrients, growth factors, and the like include, but are not limited to: coenzyme A, pantothenic acid, pyridoxine-HCl, biotin, thiamine, riboflavin, flavine mononucleotide, flavine adenine dinucleotide, DL-6,8-thioctic acid, folic acid, Vitamin B<sub>12</sub>, other vitamins, bases such as adenine, uracil, guanine, thymine and cytosine, L amino acids, sodium thiosulfate, *p- or r*-aminobenzoic acid, niacinamide, nitriloacetate, and the like, either as pure or partially purified chemical compounds or as present in natural materials. Cultivation of the inventive microorganism strain can be accomplished using any of the submerged fermentation techniques known to those skilled in the art, such as airlift, traditional sparged -agitated designs, or in shaking culture.

The culture conditions employed, including temperature, pH, aeration rate, agitation rate, culture duration, and the like, can be determined empirically by one skilled in the art to maximize amino acid production. The selection of specific culture conditions depends upon factors such as medium composition and type, culture technique, and similar considerations.

After cultivation for a sufficient period of time, until one or more kinds of amino acids that have accumulated in the cells and/or culture broth can be isolated according to any of the known methods including ion exchange chromatography, gel filtration, solvent extraction, affinity chromatography, or any combination thereof. Any method that is suitable with the conditions employed for cultivation can be used.

Preferred bacterial cells are *Corynebacterial* species and *Escherichia coli*. Preferred among bacterial cells are *Corynebacterium glutamicum* cells. As used herein, *Brevibacterium flavum* and *Brevibacterium lactofermentum* are synonymous with *Corynebacterium glutamicum*.

In the present invention, in general, increased NADPH within a microorganism is achieved by altering the carbon flux distribution between the glycolytic and pentose phosphate pathways of that organism. As used herein, "carbon flux" refers to the number of glucose molecules which proceed down a particular metabolic path relative to competing paths.

Preferably, NADPH availability is increased by increasing the carbon flux through the oxidative branch of the pentose phosphate pathway. Theoretically, 12 NADPH's are generated per glucose when glucose is exclusively metabolized in the pentose phosphate pathway, but only two NADPH's are produced per glucose metabolized in the TCA cycle (tricarboxylic acid, also called the citric acid cycle). Ishino, S. *et al.*, *J. Gen. Appl. Microbiol.* 37:157-165 (1991). The present invention provides a method of producing L-amino acids by culturing an altered bacterial cell which has an increase in the carbon flux through the pentose phosphate pathway.

Most of the glucose catabolized in living organisms proceeds through glycolysis resulting in the formation of pyruvate. The pentose phosphate pathway, also called the hexose monophosphate shunt, is an alternative route for glucose catabolism. The pentose phosphate pathway produces NADPH and under lysine fermentation conditions is more active. Ishino, S. *et al.*, *J. Gen. Appl. Microbiol.* 37:157-165 (1991).

In the present invention, an altered bacterial cell can be one in which carbon flux through the oxidative branch of the pentose phosphate pathway is increased. Specifically, in the present invention, an altered bacterial cell can be one which has an increased amount of one or more enzymes involved in the pentose phosphate pathway. Such pentose phosphate enzymes are selected from the group comprising glucose 6-phosphate dehydrogenase, transketolase, transaldolase, ribulose 5-phosphate-3-epimerase, ribulose 5-phosphate isomerase and 6-phosphogluconate dehydrogenase, and 6-phosphogluconolactonase.

In a preferred embodiment, the present invention further provides a method of producing L-amino acids by culturing an altered bacterial cell with an increased amount of malic enzyme relative to an unaltered cell. Malic enzyme catalyzes the reaction of malate with  $\text{NADP}^+$  to produce pyruvate, carbon dioxide, NADPH and  $\text{H}^+$ .

In a preferred embodiment, the present invention further provides a method of producing L-amino acids by culturing an altered bacterial cell with an increased amount of isocitrate dehydrogenase relative to an unaltered cell.

Isocitrate dehydrogenase catalyzes the reaction of isocitrate with  $\text{NADP}^+$  to produce  $\alpha$ -ketoglutarate, carbon dioxide, NADPH and  $\text{H}^+$ .

Both glycolysis and the pentose phosphate pathway compete for glucose. In the present invention, an altered bacterial cell can be one in which a decrease or blockage of the carbon flux through glycolysis results in an increase in the carbon flux through the oxidative branch of the pentose phosphate pathway. As used in the present invention, an altered bacterial cell can be one in which a decrease in carbon flux through glycolysis is achieved through decreasing the amount of one or more enzyme(s) involved in glycolysis. Preferred enzymes are 6-phosphoglucose isomerase, fructose diphosphate aldolase, D-glyceraldehyde phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, endolase or pyruvate kinase. A preferred enzyme is 6-phosphoglucose isomerase.

A preferred method of decreasing the amount of a glycolytic enzyme in an altered bacterial cell is by mutating the gene which encodes the enzyme. As used herein, preferred is blocking (null) or weakening (decreased) expression of the gene encoding 6-phosphoglucose isomerase ("*pgi*").

A preferred method of blocking (null) or weakening (decreased) expression of genes encoding enzymes involved in glycolysis is by using suicide vectors (also called integrative vectors). As used herein, a suicide vector is defined as a vector which does not replicate autonomously within a particular organism, which then is introduced into the cell and recombines into a homologous region of the organism's chromosome to cause insertional inactivation of the homologous gene. Insertional inactivation of the gene is achieved by disrupting the reading frame of the gene. Insertional inactivation of the gene occurs only if an internal portion of the gene is used as the homologous region.

Recombinant constructs can be introduced into the bacterial cells of the present invention using well known techniques such as transduction, transfection, transvection, conjugation, electroporation, electrotransformation, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, and transformation or other methods. Such methods are

described in many standard laboratory manuals, such as Davis *et al.*, "Basic Methods in Molecular Biology," (1986).

In a preferred embodiment, the altered bacterial cell is produced by (a) subcloning an internal region of the *pgi* gene into a suicide vector; and (b) inserting said suicide vector into a bacterial genome via homologous recombination. An internal region can be defined as a contiguous DNA sequence between but not including the initiation codon and final codon of the open reading frame (ORF) in question. Preferably an internal region is chosen which will facilitate genomic integration and result in the expression of a non-functional polypeptide from the ORF in question.

In certain preferred embodiments, the suicide vectors can be inducible, mutant-specific and/or condition-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives. Other suitable environmental factors will be readily apparent to the skilled artisan.

The altered bacterial cells of the present invention can be transformed with suicide vectors which optionally include at least one marker gene. Such markers include amikacin, augmentin (amoxicillin plus clavulonic acid), ampicillin, cefazolin, cefoxitin, ceftazidime, ceftiofur, cephalothin, chloramphenicol, enrofloxacin, erythromycin, florfenicol, gentamicin, imipenem, kanamycin, sarafloxacin, tetracycline, ticarcillin, streptomycin, spectinomycin, hygromycin, trimethoprim or tilmicosin resistance genes. Preferred markers include chloramphenicol and/or kanamycin resistance genes. Other suitable markers will be readily apparent to the skilled artisan.

An illustrative example of the use of suicide vectors is as follows: an internal region of a gene is amplified via the polymerase chain reaction, and the fragment resulting from the amplification is subcloned into a suicide vector which includes an antibiotic resistance marker gene, and the suicide vector is transformed into the original organism. The recovery of antibiotic resistant clones implies insertional inactivation of the homologous gene. The suicide vector used can include any plasmid incapable of autonomous replication in the target organism. In cases where the target organism is not *Escherichia coli*, Col

E1 based replicons are preferred. Among Col E1 based replicons pBGS131 (American Type Culture Collection (ATCC), Manassas, VA, Deposit No. 37443) is preferred.

In a preferred embodiment, the present invention further provides a method of producing a bacterial cell with a mutated *pgi* gene. In a particularly preferred embodiment, the invention provides a method of producing a bacterial cell with a mutated *pgi* gene comprising (a) subcloning an internal region of the *pgi* gene into a suicide vector; and (b) inserting said suicide vector into a bacterial genome via homologous recombination whereby a bacterial cell with an altered *pgi* gene is produced.

In a further embodiment, the present invention provides a bacterial cell produced according to the above-described methods.

An illustrative example of production of an altered bacterial cell follows. A region of the *Corynebacterium glutamicum* (*C. glutamicum*) *pgi* gene which encodes 6-phosphoglucose isomerase (a glycolytic enzyme), is amplified by PCR using suitable primers. Preferably, the PCR primers are those listed in SEQ ID NO:3 and SEQ ID NO:4, which contain the recognition sequence for the restriction enzyme Hind III. Following restriction with Hind III, the PCR product, is then subcloned into the suicide vector pBGS131. The resulting subclone is designated pDPTpgi2. The subclone pDPTpgi2 is then transformed into *C. glutamicum* and kanamycin resistant colonies are selected for on appropriate media. The isolation of kanamycin resistant colonies implies that an integration event has occurred. Predominantly the integration occurs via homologous recombination resulting in disruption of the *pgi* gene.

Another preferred method of producing an altered bacterial cell is by blocking or weakening expression of the appropriate gene through alteration of the promoter in front of the gene. Preferred is by using a different promoter from any source or changing the nucleotide sequence of the native promoter. Preferred among methods of changing the nucleotide sequence of the native promoter is PCR mutagenesis. Among known bacterial promoters suitable for this use in the present invention include the *E. coli lacI* and *lacZ* promoters, the T3 and T7

promoters, the *gpt* promoter, the lambda P<sub>R</sub> and P<sub>L</sub> promoters, the *trp* promoter, the *tac* promoter or promoters endogenous to the bacterial cells of the present invention. Also preferred is upregulation of genes encoding enzymes involved in the pentose phosphate pathway. This can be done by alteration of the promoter controlling the gene such that a stronger promoter than the native promoter is used. Another preferred way of upregulating the genes of the pentose phosphate pathway would be increasing the copy number of the genes in question through the use of genomic integration or autonomously replicating plasmids.

In a preferred embodiment, the present invention also provides a method of producing L-amino acids comprising culturing an altered bacterial cell, wherein said bacterial cell is a *Corynebacterium glutamicum* cell with a gene selected from the group consisting of a mutant *pgi* gene.

Another preferred method of producing an altered bacterial cell comprises mutating a gene which encodes an enzyme involved in glycolysis to produce blocked or weakened expression of the gene encoding the glycolytic enzyme. Illustrative examples of suitable methods for preparing mutated genes include, but are not limited to: PCR mutagenesis, *in vitro* chemical mutagenesis, oligonucleotide mutagenesis, mutagenesis by irradiation with ultraviolet light or X-rays, or by treatment with a chemical mutagen such as nitrosoguanidine (N-methyl-N'-nitro-N'-nitrosoguanidine), methylmethanesulfonate, nitrogen mustard and the like; gene integration techniques, such as those mediated by insertional elements or transposons or by homologous recombination of transforming linear or circular DNA molecules; and transduction mediated by bacteriophages such as P1. These methods are well known in the art and are described, for example, in J.H. Miller, *Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1972); J.H. Miller, *A Short Course in Bacterial Genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1992); M. Singer and P. Berg, *Genes & Genomes*, University Science Books, Mill Valley, California (1991); J. Sambrook, E.F. Fritsch and T. Maniatis, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); P.B. Kaufman *et al.*, *Handbook of Molecular and Cellular Methods*



in *Biology and Medicine*, CRC Press, Boca Raton, Florida (1995); *Methods in Plant Molecular Biology and Biotechnology*, B.R. Glick and J.E. Thompson, eds., CRC Press, Boca Raton, Florida (1993); and P.F. Smith-Keary, *Molecular Genetics of Escherichia coli*, The Guilford Press, New York, NY (1989).

5 In a preferred embodiment, the present invention further provides an isolated or purified bacterial cell comprising a mutated *pgi* gene.

The present invention further provides isolated nucleic acid molecules comprising a polynucleotide encoding a Pgi polypeptide having the amino acid sequence shown in Figure 1 (SEQ ID NO:2). The nucleotide sequence shown in  
10 Figure 1 (SEQ ID NO:1) can be obtained by sequencing the DNA clone, which was deposited on August 17, 1999 at the Agricultural Research Service Culture Collection (NRRL) under the terms of the Budapest Treaty, 1815 North University Street, Peoria, Illinois 61604, USA and given accession number B-30174. The deposited clone is in the p41-13(C01) plasmid.

15 The present invention provides an isolated nucleic acid molecule selected from the group consisting of:

- (a) a polynucleotide encoding a polypeptide comprising amino acids from about 1 to about 540 in SEQ ID NO:2;
- (b) a polynucleotide encoding a polypeptide comprising one of the amino acid sequences encoded by the DNA clone contained in NRRL Deposit No. B-30174;
- (c) the complement of (a) or (b);
- (d) a polynucleotide variant created by altering the polynucleotide of (a), wherein:
  - 25 (1) said altering includes a nucleotide insertion, deletion, or substitution, or any combination thereof; and
  - (2) the number of alterations is equal to or less than 5 % of the total number of nucleotides present in  
30 (a);

(e) a polynucleotide variant created by altering the polynucleotide of (b), wherein:

- (1) said altering includes a nucleotide insertion, deletion, or substitution, or any combination thereof; and
- (2) the number of alterations is equal to or less than 5 % of the total number of nucleotides present in (b);

(f) a polynucleotide variant created by altering the polynucleotide of (c), wherein:

- (1) said altering includes a nucleotide insertion, deletion, or substitution, or any combination thereof; and
- (2) the number of alterations is equal to or less than 5 % of the total number of nucleotides present in (c).

The present invention further provides the above nucleic acid molecule wherein said polynucleotide has the complete nucleotide sequence in SEQ ID NO:1.

The present invention further provides the above nucleic acid molecule wherein said polynucleotide has the nucleotide sequence in SEQ ID NO:1 encoding the Pgi polypeptide having the complete amino acid sequence in SEQ ID NO:2.

The present invention further provides the above nucleic acid molecule wherein said polynucleotide has a nucleotide sequence encoding the Pgi polypeptide encoded by a DNA clone contained in NRRL Deposit No. B-30174.

The present invention further provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), or (c) of the above nucleic acid molecule, wherein said polynucleotide which hybridizes does not hybridize under stringent

hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.

The present invention further provides a method for making a recombinant vector comprising inserting the above isolated nucleic acid molecule into a vector.

The present invention further provides a vector comprising the above nucleic acid molecule. The present invention further provides a method of making a recombinant host cell comprising introducing the above vector into a host cell. The present invention further provides a host cell comprising the above vector. The present invention further provides a method for producing a Pgi polypeptide, comprising culturing the above recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide.

The present invention further provides an isolated polypeptide selected from the group consisting of:

- (a) a polypeptide comprising amino acids from about 1 to about 540 in SEQ ID NO:2;
- (b) a polypeptide comprising the amino acid sequence encoded by the DNA clone contained in NRRL Deposit No. B-30174;
- (c) a polypeptide variant created by altering the amino acid sequence of (a), wherein:
  - (1) said altering includes an insertion, deletion, or substitution, or any combination thereof; and
  - (2) the number of alterations is equal to or less than 5 % of the total number of amino acids present in (a);
- (d) a polypeptide variant created by altering the polynucleotide of (b), wherein:
  - (1) said altering includes an insertion, deletion, or substitution, or any combination thereof; and

- (2) the number of alterations is equal to or less than 5 % of the total number of amino acids present in (b).

### ***Nucleic Acid Molecules***

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

Using the information provided herein, such as the nucleotide sequence in Figure 1, a nucleic acid molecule of the present invention encoding a Pgi polypeptide may be obtained using standard cloning and screening procedures.

Thus, the present invention provides a nucleotide sequence encoding the Pgi polypeptide having the amino acid sequence encoded by the clone contained in the host identified as NRRL Deposit No. B-30174 and as shown in Figures 1 (SEQ ID NOs:1 and 2).

As one of ordinary skill would appreciate, due to the possibilities of sequencing errors, the predicted Pgi polypeptide encoded by the deposited clone comprise about 540 amino acids, but may be anywhere in the range of 500 to 580 amino acids.

As indicated, nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) shown in Figure 1 (SEQ ID NO:1); DNA molecules comprising the coding sequence for the Pgi protein shown in Figures 1 (SEQ ID NO:2); and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the Pgi protein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate variants.

In addition, the invention provides nucleic acid molecules having nucleotide sequences related to extensive portions of SEQ ID NO:1.

In another aspect, the invention provides isolated nucleic acid molecules encoding the Pgi polypeptide having an amino acid sequence encoded by the nucleic acid molecule deposited as NRRL Deposit No. B-30174 on August 17, 1999. The invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) or the nucleotide sequence of the *pgi* genomic sequence contained in the above-described deposited clone, or a nucleic acid molecule having a sequence

complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, by in situ hybridization with chromosomes.

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule having the nucleotide sequence of the deposited clone or the nucleotide sequence shown in Figure 1 (SEQ ID NOs:1) is intended fragments at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 50, 75, 100, 125, 150, 175, 200, 225, 250, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550 nt in length are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence of the deposited clone or as shown in Figure 1 (SEQ ID NOs:1). By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited clone or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1).

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the deposited clone contained in NRRL Deposit B-30174. By "stringent hybridization conditions" is intended overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

By a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30-70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above and in more detail below.

By a portion of a polynucleotide of "at least 20 nt in length," for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., the deposited clone or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1). Of course, a polynucleotide which hybridizes only to a polyA sequence (such as the 3' terminal poly(A) tract of the pgi cDNA shown in Figure 1 (SEQ ID NO:1)), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

As indicated, nucleic acid molecules of the present invention which encode a Pgi polypeptide may include, but are not limited to those encoding the amino acid sequence of the polypeptide, by itself; the coding sequence for the polypeptide and additional sequences, such as those encoding an amino acid leader or secretory sequence, such as a pre-, or pro- or prepro- protein sequence; the coding sequence of the polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, for example - ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz *et al.*, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been

described by Wilson *et al.*, *Cell* 37: 767 (1984). As discussed below, other such fusion proteins include the Pgi fused to Fc at the – or C-terminus.

The probes, primers, and/or nucleic acid fragments described above can be used to monitor expression of the *pgi* gene during fermentation.

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the Pgi protein. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. *Genes II*, Lewin, B., ed., John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Such variants include those produced by nucleotide substitutions, deletions or additions, which may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the Pgi protein or portions thereof. Also especially preferred in this regard are conservative substitutions.

Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 95%, 96%, 97%, 98% or 99% identical to (a) a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2; (b) a nucleotide sequence encoding the full-length Pgi polypeptide having the complete amino acid sequence encoded by the clone contained in NRRL Deposit No. B-30174; or (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b).

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a Pgi polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide



sequence encoding the Pgi polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 95%, 96%, 97%, 98% or 99% identical to, for instance, the nucleotide sequence shown in Figure 1 or to the nucleotides sequence of the deposited clones can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711. Bestfit uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2: 482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

The present application is directed to nucleic acid molecules at least 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1) or to the nucleic acid sequence of the deposited clone, irrespective of whether they encode a polypeptide having Pgi activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having Pgi activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase

chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having Pgi activity include, inter alia, isolating the *pgi* gene or allelic variants thereof in a genomic library and Northern Blot analysis for detecting *pgi* mRNA expression.

5 Preferred, however, are nucleic acid molecules having sequences at least 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1) or to the nucleic acid sequence of the deposited clone which do, in fact, encode a polypeptide having Pgi protein activity. By "a polypeptide having Pgi activity" is intended polypeptides exhibiting activity  
10 similar, but not necessarily identical, to an activity of the Pgi protein of the invention, as measured in a particular biological assay.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of the deposited clone or the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1) will encode a polypeptide "having Pgi protein activity." In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized  
15 in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having Pgi protein activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).  
20

25 For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," I:1306-1310 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions.

### ***Vectors and Host Cells***

The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of Pgi polypeptides or fragments thereof by recombinant techniques.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp* and *tac* promoters to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include but are not limited to kanamycin chloramphenicol, tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among known bacterial promoters suitable for use in the production of proteins of the present invention include the *E. coli lacI* and *lacZ* promoters, the T3 and T7 promoters, the *gpt* promoter, the lambda PR and PL promoters and the *trp* promoter.

Thus, the present invention is also directed to expression vector useful for the production of the proteins of the present invention.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia.

5 Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such

10 as Davis *et al.*, *Basic Methods In Molecular Biology* (1986).

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during

15 purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques

20 in the art.

The Pgi protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,

25 phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures,

30 and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant

production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

### ***Pgi Polypeptides and Fragments***

The invention further provides an isolated Pgi polypeptide having the amino acid sequence encoded by the deposited clone, or the amino acid sequence in Figure 1 (SEQ ID NO:2), or a peptide or polypeptide comprising a portion of the above polypeptides.

It will be recognized in the art that some amino acid sequences of the Pgi polypeptide can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity.

Thus, the invention further includes variations of the Pgi polypeptide which show substantial Pgi polypeptide activity or which include regions of Pgi protein such as the protein portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and type substitutions. As indicated above, guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

Thus, the fragment, derivative or analog of the polypeptide of Figure 1 (SEQ ID NO:2), or the Pgi polypeptide encoded by the deposited clone, may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional

amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 1).

TABLE 1. Conservative Amino Acid Substitutions.

Aromatic	Phenylalanine Tryptophan Tyrosine
Hydrophobic	Leucine Isoleucine Valine
Polar	Glutamine Asparagine
Basic	Arginine Lysine Histidine
Acidic	Aspartic Acid Glutamic Acid
Small	Alanine Serine Threonine Methionine Glycine

Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of amino acid substitutions for any given Pgi polypeptide will not be more than 50, 40, 30, 20, 10, 5, or 3.

Amino acids in the Pgi protein of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations

at every residue in the molecule. The resulting mutant molecules are then tested for phosphoglucose isomerase activity.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, partially or substantially, from a recombinant host cell. For example, a recombinantly produced version of the Pgi polypeptide can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).

The polypeptides of the present invention include the Pgi polypeptide encoded by the deposited DNA and polypeptides which are at least 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptides encoded by the deposited clone, to the polypeptide of Figure 1 (SEQ ID NO:2), and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a Pgi polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the Pgi polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in Figures 1 (SEQ ID NO:2) or to the amino acid sequence encoded by deposited clones can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

The polypeptide of the present invention could be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.

#### ***N-terminal and C-terminal Deletion Mutants***

In one embodiment, the present invention provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of the Pgi polypeptide depicted in Figure 1 or encoded by the DNA of the deposited clone. Particularly, in one embodiment, N-terminal deletions of the Pgi polypeptide can be described by the general formula m to 540, where m is any one of the integers from 2 to 539 corresponding to the position of the amino acid residue identified in SEQ ID NO:2 and, preferably, corresponds to one of the N-terminal amino acid residues identified in the N-terminal deletions specified herein. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further embodiments of the invention are directed to C-terminal deletions of the Pgi polypeptides of the invention, described by the general formula 1 to n, where n is any one of the integers from 2 to 539 corresponding to the position of



amino acid residue identified in SEQ ID NO:2, and preferably corresponds to a residue identified in one of the C-terminal deletions specified herein. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further embodiments of the invention are directed to polypeptide fragments comprising, or alternatively, consisting of, amino acid residues described by the general formula m to n, where m and n correspond to any one of the amino acid residues specified above for these symbols, respectively. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The following examples are illustrative only and are not intended to limit the scope of the invention as defined by the appended claims. It will be apparent to those skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

## ***Examples***

### ***Example 1 - DNA Isolation and Purification***

DNA was isolated from cultures of NRRL B-11474 cells. NRRL B-11474 cells were harvested from CM media (Table B) and suspended in 10 ml of TE pH 8 (10 mM Tris\*Cl, 1 mM EDTA). Forty micrograms of RNase A and 10 milligrams of lysozyme were added per milliliter of suspension and the suspension was incubated at 37°C for 30 minutes. The suspension was made 1.0% in sodium dodecyl sulfate (SDS) and 0.1 mg/l proteinase K was added, and the cells were lysed by incubation at 37°C for 10 minutes. Nucleic acids were purified by three extractions with TE-saturated phenol (pH 7), followed by ethanol precipitation. Nucleic acid precipitates were twice washed with 80% ethanol and redissolved in TE pH 8. The concentrations of DNA were quantified

spectrophotometrically at 260 nm. Purity of DNA preparations were determined spectrophotometrically (A260/A280 and A260/A230 ratios) and by agarose gel electrophoresis (0.8% agarose in 1xTAE).

Sequencing of genomic DNA was performed, as is known by one of ordinary skill in the art, by creating libraries of plasmids and cosmids using pGEM3 and Lorist 6, respectively. The *C. glutamicum* *pgi* gene was identified by homology to glucose-6-phosphate isomerase of *Mycobacterium tuberculosis* (Swiss Prot Accession number P77895, Swiss Prot ID G6PI\_MYCTU).

### **Example 2 - Increasing NADPH Availability by Disrupting *pgi***

An increase in carbon flux through the oxidative branch of the pentose phosphate pathway was achieved by disrupting the *pgi* gene which encodes 6-phosphoglucose isomerase. Two PCR primers were designed from the genomic DNA sequence described above to facilitate the amplification of a 680 bp internal region of the *C. glutamicum* *pgi* gene. These primers were:

pgif\* (SEQ ID NO:3) 5' gctgatgtccacgaagctttgggac 3'

pgir\* (SEQ ID NO:4) 3' gctgagaaccttggaataaggtagg 3'

Primers pgif\* and pgir\* contain the recognition sequence for the restriction enzyme Hind III. In the case of pgir\*, it was necessary to make three changes from the *C. glutamicum* nucleotide sequence to incorporate the Hind III recognition sequence. These Hind III restriction sites facilitated subcloning.

PCR amplification conditions were employed as follows. The final volume of each PCR reaction was 100  $\mu$ l. 100 ng of each primer was used along with 50 ng of high molecular weight *C. glutamicum* ATCC 21799 genomic DNA and 2.5 units of Taq DNA polymerase. Reaction buffer was included at a concentration recommended by the manufacturer (Stratagene) and dNTPs were also included at a final concentration of 200  $\mu$ M. Cycling parameters were as follows: 94  $^{\circ}$ C for 1 minute, followed by 94  $^{\circ}$ C for 30 seconds, 60  $^{\circ}$ C for 30

seconds and 72 °C for 1 minute (30 cycles), 72 °C for 7 minutes followed by refrigeration.

On restriction with Hind III, the PCR product was reduced in size to approximately 660 bp. This fragment was then subcloned into the suicide vector pBGS131. The resulting subclone was designated pDPTpgi2.

Following electrotransformation into competent *C. glutamicum* (NRRL B11474) cells, integrants were selected for on CM (Table B) agar plates containing kanamycin at a final concentration of 10 µg/ml. Enzyme assay confirmed the absence of phosphoglucose isomerase activity in the mutant strains, indicating that the *pgi* gene in these strains had been disrupted.

Shake flask experiments indicate that the *C. glutamicum* (NRRL B11474) *pgi* mutants have improved lysine titers and yields when compared to *C. glutamicum* (NRRL B11474) (Table A).

**Table A: Lysine production on FM3 (Table C) media**

Strain	Growth	Titer	Yield
NRRL B11474	46	25	42
NRRL B11474::pgi2A	40	31	52
Growth	= optical density at 660 nm		
Titer	= grams of lysine / liter of medium		
Yield	= (grams of lysine / grams of glucose consumed)*100		

**Table B: CM Media**

Volume:	1000 ml	% Agar:	0
	Sucrose	50 g	
	KH <sub>2</sub> PO <sub>4</sub>	0.5 g	
5	K <sub>2</sub> HPO <sub>4</sub>	1.5 g	
	Urea	3 g	
	MgSO <sub>4</sub> * 7H <sub>2</sub> O	0.5 g	
	Polypeptone	20 g	
	Beef Extract	5 g	
10	Biotin	12.5 ml (60mg/L)	
	Thiamine	25 ml (120mg/L)	
	Niacinamide	25 ml (5g/L)	
	L-Methionine	0.5 g	
	L-Threonine	0.25 g	
15	L-Alanine	0.5 g	
	Bring to volume	1000 mls with DI water.	
	pH - about 7.1		

**Table C: FM3 Media**

Per liter

20	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	50g
	KH <sub>2</sub> PO <sub>4</sub>	1g
	MgSO <sub>4</sub> *7H <sub>2</sub> O	0.4g
	MnSO <sub>4</sub> *H <sub>2</sub> O	0.01g
	FeSO <sub>4</sub> *7H <sub>2</sub> O	0.01g
25	Biotin	0.03mg
	Corn Steep Liquor	4% dry solids final concentration
	Glucose	6% final concentration
	CaCO <sub>3</sub>	50g

**Example 3 - Disrupting the Gene Encoding 6-Phosphofructokinase (pfkA)**

The gene encoding for 6-phosphofructokinase (pfkA) was disrupted in a method similar to that described for the *pgi* gene in Example 2. Disruption of the *pfkA* gene was verified by enzyme assay of extracts of the mutants and showed

that 6-phosphofructokinase activity was lacking. Unexpectedly, the *C. glutamicum* (NRRL B-11474) pfkA mutants were unable to utilize glucose.

\* \* \* \* \*

All patents and publications referred to herein are hereby expressly incorporated in their entirety by reference.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.

### ***What Is Claimed Is:***

1. A method of producing L-amino acids comprising:  
culturing an altered bacterial cell having an increased amount of  
NADPH as compared to an unaltered bacterial cell, wherein L-amino acid yields  
from said altered bacterial cell are greater than yields from an unaltered bacterial  
cell.

2. The method of claim 1, wherein said altered bacterial cell has  
increased carbon flux through the oxidative branch of the pentose phosphate  
pathway.

3. The method of claim 2, wherein said altered bacterial cell has an  
increased amount of one or more enzymes selected from the group comprising  
glucose-6-phosphate dehydrogenase, lactonase and 6-phosphogluconate  
dehydrogenase.

4. The method of claim 1, wherein said altered bacterial cell has a  
decreased carbon flux through the glycolytic pathway.

5. The method of claim 4, wherein said altered bacterial cell has a  
decreased amount of 6-phosphoglucose isomerase enzymatic activity.

6. The method of claim 1, wherein said L-amino acid yields from  
said altered bacterial cell are from about 1% to about 100% greater than from said  
unaltered bacterial cell.

7. The method of claim 1, wherein said altered bacterial cell has a  
mutant *pgi* gene.

8. The method of claim 1, wherein said altered bacterial cell is  
produced by

- (a) subcloning an internal region of a *pgi* gene; and
- (b) inserting said resulting vector from step (a) into a bacterial genome via homologous recombination.

9. The method of claim 1, wherein said altered bacterial cell has an increased amount of malic enzyme.

10. The method of claim 1, wherein said altered bacterial cell has an increased amount of isocitrate dehydrogenase.

11. The method of claim 1, wherein said altered bacterial cell is a *Corynebacterium glutamicum* cell.

12. The method of claim 11, wherein said *Corynebacterium glutamicum* cell has a gene selected from the group consisting of a mutated *pgi* gene.

13. The method of claim 1, wherein said L-amino acid comprises L-lysine.

14. A vector comprising pDPT<sub>pgi</sub>2.

15. A method of producing a bacterial cell with a mutated *pgi* gene comprising:

- (a) subcloning an internal region of the *pgi* gene into a suicide vector; and
- (b) inserting said resulting vector from step (a) into a bacterial genome whereby a bacterial cell with an altered *pgi* gene is produced.

16. The method of claim 15, wherein said suicide vector is selected from the group comprising pBGS131 and Col E1 based replicons with selectable marker.

17. An altered bacterial cell produced according to the method of claim 15.

18. A method of producing L-amino acids comprising:  
culturing an altered bacterial cell having a decreased amount of 6-phosphoglucose isomerase enzymatic activity as compared to an unaltered bacterial cell wherein L-amino acid yields from said altered bacterial cell are greater than yields from an unaltered bacterial cell.

19. The method of claim 18, wherein said L-amino acid yields from said altered bacterial cell are from about 1% to about 100% greater than from said unaltered bacterial cell.

20. The method of claim 18, wherein said altered bacterial cell has a mutant *pgi* gene.

21. The method of claim 18, wherein said altered bacterial cell is produced by

- (a) subcloning an internal region of a *pgi* gene; and
- (b) inserting said resulting vector from step (a) into a bacterial genome via homologous recombination.

22. The method of claim 18, wherein said altered bacterial cell is a *Corynebacterium glutamicum* cell.

23. The method of claim 18, wherein said L-amino acid comprises L-lysine.



# Methods for Producing L-Amino Acids

## *Abstract*

The present invention relates, in general, to a method of producing L-amino acids comprising culturing altered bacterial cells having increased amounts of NADPH as compared to unaltered bacterial cells whereby L-amino acids yields from said altered bacterial cells are greater than yields from unaltered bacterial cells. The invention also relates to a gene encoding phosphoglucoisomerase.

A270-36 wpd

ATGGCGGACATTTGACCACCCAGGCTTGGCAAGACCTGACCGATCATTACTCAAAC TTC  
 1 -----+-----+-----+-----+-----+-----+-----+ 60  
 M A D I S T T Q A W Q D L T D H Y S N F  
 CAGGCAACCACTCTGCGTGAAC TTTTCAAGGAAGAAAACCGCGCCGAGAAGTACAC TTC  
 61 -----+-----+-----+-----+-----+-----+-----+ 120  
 Q A T T L R E L F K E E N R A E K Y T F  
 TCCGCGGCTGGCCTCCACGTCGACCTGTGGAAGAATCTGCTTGACGACGCCACCCTCACC  
 121 -----+-----+-----+-----+-----+-----+-----+ 180  
 S A A G L H V D L S K N L L D D A T L T  
 AAGCTCCTTGCACTGACCGAAGAATCTGGCCTTCGCGAACGCATTGACGCGATGTTTGCC  
 181 -----+-----+-----+-----+-----+-----+-----+ 240  
 K L L A L T E E S G L R E R I D A M F A  
 GGTGAACACCTCAACAACACCGAAGACCGCGCTGTCTCCACACCGCGCTGCGCCTTCCCT  
 241 -----+-----+-----+-----+-----+-----+-----+ 300  
 G E H L N N T E D R A V L H T A L R L P  
 CCCGAAGCTGATCTGTGCTAGTAGGCCAAGATGTTGCTGCTGATGTCCACGAAGTTTGTG  
 301 -----+-----+-----+-----+-----+-----+-----+ 360  
 P E A D L S V D G Q D V A A D V H E V L  
 GGACGCATGCGTGACTTCGCTACTGCGCTGCGCTCAGGCAACTGGTTGGGACACACCGGC  
 361 -----+-----+-----+-----+-----+-----+-----+ 420  
 G R M R D F A T A L R S G N W L G H T G  
 CACACGATCAAGAAGATCGTCAACATTGGTATCGGTGGCTCTGACCTCGGACCAGCCATG  
 421 -----+-----+-----+-----+-----+-----+-----+ 480  
 H T I K K I V N I G I G G S D L G P A M  
 GCTACGAAGGCTCTGCGTGCATACGCGACCGCTGGTATCTCAGCAGAATTCGTCTCCAAC  
 481 -----+-----+-----+-----+-----+-----+-----+ 540  
 A T K A L R A Y A T A G I S A E F V S N  
 GTCGACCCAGCAGACCTCGTTTCTGTGTTGGAAGACCTCGATGCAGAATCCACATTGTTTC  
 541 -----+-----+-----+-----+-----+-----+-----+ 600  
 V D P A D L V S V L E D L D A E S T L F

FIG.1A

GTGATCGCTTCGAAAACTTTTACCACCCAGGAGACGCTGTCTAACGCTCGTGCGAGCTCGT  
 601 -----+-----+-----+-----+-----+-----+-----+ 660  
 V I A S K T F T T Q E T L S N A R A A R  
 GCTTGGCTGGTAGAGAAGCTCGGTGAAGAGGCTGTGCGGAAGCATTTGTCGCGAGTGTCC  
 661 -----+-----+-----+-----+-----+-----+-----+ 720  
 A W L V E K L G E E A V A K H F V A V S  
 ACCAATGCTGAAAAGGTCGCAGAGTTCGGTATCGACACGGACAACATGTTGGCTTCTGG  
 721 -----+-----+-----+-----+-----+-----+-----+ 780  
 T N A E K V A E F G I D T D N M F G F W  
 GACTGGGTCGGAGGTCGTTACTCCGTGGACTCCGCAGTTGGTCTTCCCTCATGGCAGTG  
 781 -----+-----+-----+-----+-----+-----+-----+ 840  
 D W V G G R Y S V D S A V G L S L M A V  
 ATCGGCCCTCGCGACTTCATGCGTTTCTCGGTGGATTCCACGCGATGGATGAACACTTC  
 841 -----+-----+-----+-----+-----+-----+-----+ 900  
 I G P R D F M R F L G G F H A M D E H F  
 CGCACCAACGTTCTGAAGAGAACGTTCCAATCTTGATGGCTCTGCTCGGTGTCTGGTAC  
 901 -----+-----+-----+-----+-----+-----+-----+ 960  
 R T T K F E E N V P I L M A L L G V W Y  
 TCCGATTCTATGGTGCAGAAACCCACGCTGTCTACCTTATTCCGAGGATCTCAGCCGT  
 961 -----+-----+-----+-----+-----+-----+-----+ 1020  
 S D F Y G A E T H A V L P Y S E D L S R  
 TTTGCTGCTTACCTCCAGCAGCTGACCATGGAATCAAACGGCAAGTCAGTCCACCGCGAC  
 1021 -----+-----+-----+-----+-----+-----+-----+ 1080  
 F A A Y L Q Q L T M E S N G K S V H R D  
 GGCTCCCTGTTTCCACTGGCACTGGCGAAATTTACTGGGGTGAGCTGGCACAAATGGC  
 1081 -----+-----+-----+-----+-----+-----+-----+ 1140  
 G S P V S T G T G E I Y W G E P G T N G  
 CAGCACGCTTTCTTCCAGCTGATCCACGAGGCACTCGCCTTGTTCCAGCTGATTTTCATT  
 1141 -----+-----+-----+-----+-----+-----+-----+ 1200  
 Q H A F F Q L I H Q G T R L V P A D F I

FIG.1B

1201 GGTTCGCTCGTCCAAAGCAGGATCTTCCTGCCGGTGAGCGCACCATGCATGACCTTTTG 1260  
 -----+-----+-----+-----+-----+-----+  
 G F A R P K Q D L P A G E R T M H D L L  
 1261 ATGAGCAACTTCTTCGCACAGACCAAGGTTTTGGCTTTCGGTAAGAACGCTGAAGAGATC 1320  
 -----+-----+-----+-----+-----+-----+  
 M S N F F A Q T K V L A F G K N A E E I  
 1321 GCTGCCGAAGGTGTCGCACCTGAGCTGGTCAACCACAAGGTCATGCCAGGTAATCGCCCA 1380  
 -----+-----+-----+-----+-----+-----+  
 A A E G V A P E L V N H K V M P G N R P  
 1381 ACCACCACCATTTTGGCGGAGGAACCTACCCCTTCTATTCTCGGTGCGTTGATCGCTTTG 1440  
 -----+-----+-----+-----+-----+-----+  
 T T T I L A E E L T P S I L G A L I A L  
 1441 TACGAACACATCGTGATGGTTCAGGGCGTGATTTGGGACATCAACTCCTTCGACCAATGG 1500  
 -----+-----+-----+-----+-----+-----+  
 Y E H I V M V Q G V I W D I N S F D Q W  
 1501 GGTGTTGAACTGGGCAAACAGCAGGCAAATGACCTCGCTCCGGCTGTCTCTGGTGAAGAG 1560  
 -----+-----+-----+-----+-----+-----+  
 G V E L G K Q Q A N D L A P A V S G E E  
 1561 GATGTTGACTCGGGAGATTCTTCCACTGATTCACTGATTAAGTGGTACCGCGCAAATAGG 1620  
 -----+-----+-----+-----+-----+-----+  
 D V D S G D S S T D S L I K W Y R A N R  
 TAG  
 1621 --- 1623

★

FIG.1C

SEQUENCE LISTING

<110> O'Donohue, Michael R.  
Hanke, Paul D.

<120> Methods for Producing L-Amino Acids

<130> 1533.1010002

<140>

<141>

<150> 60/150,017

<151> 1999-08-20

<150> 60/145,217

<151> 1999-07-23

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 1623

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (1)..(1620)

<400> 1

```
atg gcg gac att tcg acc acc cag gct tgg caa gac ctg acc gat cat 48
Met Ala Asp Ile Ser Thr Thr Gln Ala Trp Gln Asp Leu Thr Asp His
1 5 10 15

tac tca aac ttc cag gca acc act ctg cgt gaa ctt ttc aag gaa gaa 96
Tyr Ser Asn Phe Gln Ala Thr Thr Leu Arg Glu Leu Phe Lys Glu Glu
20 25 30

aac cgc gcc gag aag tac acc ttc tcc gcg gct ggc ctc cac gtc gac 144
Asn Arg Ala Glu Lys Tyr Thr Phe Ser Ala Ala Gly Leu His Val Asp
35 40 45

ctg tcg aag aat ctg ctt gac gac gcc acc ctc acc aag ctc ctt gca 192
Leu Ser Lys Asn Leu Leu Asp Asp Ala Thr Leu Thr Lys Leu Leu Ala
50 55 60

ctg acc gaa gaa tct ggc ctt cgc gaa cgc att gac gcg atg ttt gcc 240
Leu Thr Glu Glu Ser Gly Leu Arg Glu Arg Ile Asp Ala Met Phe Ala
65 70 75 80

ggg gaa cac ctc aac aac acc gaa gac cgc gct gtc ctc cac acc gcg 288
Gly Glu His Leu Asn Asn Thr Glu Asp Arg Ala Val Leu His Thr Ala
85 90 95

ctg cgc ctt cct ccc gaa gct gat ctg tca gta gat ggc caa gat gtt 336
Leu Arg Leu Pro Pro Glu Ala Asp Leu Ser Val Asp Gly Gln Asp Val
100 105 110

gct gct gat gtc cac gaa gtt ttg gga cgc atg cgt gac ttc gct act 384
```

Ala Ala Asp Val His Glu Val Leu Gly Arg Met Arg Asp Phe Ala Thr	
115 120 125	
gcg ctg cgc tca ggc aac tgg ttg gga cac acc ggc cac acg atc aag	432
Ala Leu Arg Ser Gly Asn Trp Leu Gly His Thr Gly His Thr Ile Lys	
130 135 140	
aag atc gtc aac att ggt atc ggt ggc tct gac ctc gga cca gcc atg	480
Lys Ile Val Asn Ile Gly Ile Gly Gly Ser Asp Leu Gly Pro Ala Met	
145 150 155 160	
gct acg aag gct ctg cgt gca tac gcg acc gct ggt atc tca gca gaa	528
Ala Thr Lys Ala Leu Arg Ala Tyr Ala Thr Ala Gly Ile Ser Ala Glu	
165 170 175	
ttc gtc tcc aac gtc gac cca gca gac ctc gtt tct gtg ttg gaa gac	576
Phe Val Ser Asn Val Asp Pro Ala Asp Leu Val Ser Val Leu Glu Asp	
180 185 190	
ctc gat gca gaa tcc aca ttg ttc gtg atc gct tcg aaa act ttt acc	624
Leu Asp Ala Glu Ser Thr Leu Phe Val Ile Ala Ser Lys Thr Phe Thr	
195 200 205	
acc cag gag acg ctg tct aac gct cgt gca gct cgt gct tgg ctg gta	672
Thr Gln Glu Thr Leu Ser Asn Ala Arg Ala Ala Arg Ala Trp Leu Val	
210 215 220	
gag aag ctc ggt gaa gag gct gtc gcg aag cat ttc gtc gca gtg tcc	720
Glu Lys Leu Gly Glu Glu Ala Val Ala Lys His Phe Val Ala Val Ser	
225 230 235 240	
acc aat gct gaa aag gtc gca gag ttc ggt atc gac acg gac aac atg	768
Thr Asn Ala Glu Lys Val Ala Glu Phe Gly Ile Asp Thr Asp Asn Met	
245 250 255	
ttc ggc ttc tgg gac tgg gtc gga ggt cgt tac tcc gtg gac tcc gca	816
Phe Gly Phe Trp Asp Trp Val Gly Gly Arg Tyr Ser Val Asp Ser Ala	
260 265 270	
gtt ggt ctt tcc ctc atg gca gtg atc ggc cct cgc gac ttc atg cgt	864
Val Gly Leu Ser Leu Met Ala Val Ile Gly Pro Arg Asp Phe Met Arg	
275 280 285	
ttc ctc ggt gga ttc cac gcg atg gat gaa cac ttc cgc acc acc aag	912
Phe Leu Gly Gly Phe His Ala Met Asp Glu His Phe Arg Thr Thr Lys	
290 295 300	
ttc gaa gag aac gtt cca atc ttg atg gct ctg ctc ggt gtc tgg tac	960
Phe Glu Glu Asn Val Pro Ile Leu Met Ala Leu Leu Gly Val Trp Tyr	
305 310 315 320	
tcc gat ttc tat ggt gca gaa acc cac gct gtc cta cct tat tcc gag	1008
Ser Asp Phe Tyr Gly Ala Glu Thr His Ala Val Leu Pro Tyr Ser Glu	
325 330 335	
gat ctc agc cgt ttt gct gct tac ctc cag cag ctg acc atg gaa tca	1056
Asp Leu Ser Arg Phe Ala Ala Tyr Leu Gln Gln Leu Thr Met Glu Ser	
340 345 350	
aac ggc aag tca gtc cac gcg gac ggc tcc cct gtt tcc act ggc act	1104
Asn Gly Lys Ser Val His Arg Asp Gly Ser Pro Val Ser Thr Gly Thr	
355 360 365	

ggc gaa att tac tgg ggt gag cct ggc aca aat ggc cag cac gct ttc 1152  
Gly Glu Ile Tyr Trp Gly Glu Pro Gly Thr Asn Gly Gln His Ala Phe  
370 375 380

ttc cag ctg atc cac cag ggc act cgc ctt gtt cca gct gat ttc att 1200  
Phe Gln Leu Ile His Gln Gly Thr Arg Leu Val Pro Ala Asp Phe Ile  
385 390 395 400

ggc ttc gct cgt cca aag cag gat ctt cct gcc ggt gag cgc acc atg 1248  
Gly Phe Ala Arg Pro Lys Gln Asp Leu Pro Ala Gly Glu Arg Thr Met  
405 410 415

cat gac ctt ttg atg agc aac ttc ttc gca cag acc aag gtt ttg gct 1296  
His Asp Leu Leu Met Ser Asn Phe Phe Ala Gln Thr Lys Val Leu Ala  
420 425 430

ttc ggt aag aac gct gaa gag atc gct gcg gaa ggt gtc gca cct gag 1344  
Phe Gly Lys Asn Ala Glu Glu Ile Ala Ala Glu Gly Val Ala Pro Glu  
435 440 445

ctg gtc aac cac aag gtc atg cca ggt aat cgc cca acc acc acc att 1392  
Leu Val Asn His Lys Val Met Pro Gly Asn Arg Pro Thr Thr Thr Ile  
450 455 460

ttg gcg gag gaa ctt acc cct tct att ctc ggt gcg ttg atc gct ttg 1440  
Leu Ala Glu Glu Leu Thr Pro Ser Ile Leu Gly Ala Leu Ile Ala Leu  
465 470 475 480

tac gaa cac atc gtg atg gtt cag ggc gtg att tgg gac atc aac tcc 1488  
Tyr Glu His Ile Val Met Val Gln Gly Val Ile Trp Asp Ile Asn Ser  
485 490 495

ttc gac caa tgg ggt gtt gaa ctg ggc aaa cag cag gca aat gac ctc 1536  
Phe Asp Gln Trp Gly Val Glu Leu Gly Lys Gln Gln Ala Asn Asp Leu  
500 505 510

gct ccg gct gtc tct ggt gaa gag gat gtt gac tcg gga gat tct tcc 1584  
Ala Pro Ala Val Ser Gly Glu Glu Asp Val Asp Ser Gly Asp Ser Ser  
515 520 525

act gat tca ctg att aag tgg tac cgc gca aat agg tag 1623  
Thr Asp Ser Leu Ile Lys Trp Tyr Arg Ala Asn Arg  
530 535 540

<210> 2

<211> 540

<212> PRT

<213> *Corynebacterium glutamicum*

<400> 2

Met Ala Asp Ile Ser Thr Thr Gln Ala Trp Gln Asp Leu Thr Asp His  
1 5 10 15

Tyr Ser Asn Phe Gln Ala Thr Thr Leu Arg Glu Leu Phe Lys Glu Glu  
20 25 30

Asn Arg Ala Glu Lys Tyr Thr Phe Ser Ala Ala Gly Leu His Val Asp  
35 40 45

Leu Ser Lys Asn Leu Leu Asp Asp Ala Thr Leu Thr Lys Leu Leu Ala  
50 55 60

Leu Thr Glu Glu Ser Gly Leu Arg Glu Arg Ile Asp Ala Met Phe Ala  
 65 70 75 80  
 Gly Glu His Leu Asn Asn Thr Glu Asp Arg Ala Val Leu His Thr Ala  
 85 90 95  
 Leu Arg Leu Pro Pro Glu Ala Asp Leu Ser Val Asp Gly Gln Asp Val  
 100 105 110  
 Ala Ala Asp Val His Glu Val Leu Gly Arg Met Arg Asp Phe Ala Thr  
 115 120 125  
 Ala Leu Arg Ser Gly Asn Trp Leu Gly His Thr Gly His Thr Ile Lys  
 130 135 140  
 Lys Ile Val Asn Ile Gly Ile Gly Gly Ser Asp Leu Gly Pro Ala Met  
 145 150 155 160  
 Ala Thr Lys Ala Leu Arg Ala Tyr Ala Thr Ala Gly Ile Ser Ala Glu  
 165 170 175  
 Phe Val Ser Asn Val Asp Pro Ala Asp Leu Val Ser Val Leu Glu Asp  
 180 185 190  
 Leu Asp Ala Glu Ser Thr Leu Phe Val Ile Ala Ser Lys Thr Phe Thr  
 195 200 205  
 Thr Gln Glu Thr Leu Ser Asn Ala Arg Ala Ala Arg Ala Trp Leu Val  
 210 215 220  
 Glu Lys Leu Gly Glu Glu Ala Val Ala Lys His Phe Val Ala Val Ser  
 225 230 235 240  
 Thr Asn Ala Glu Lys Val Ala Glu Phe Gly Ile Asp Thr Asp Asn Met  
 245 250 255  
 Phe Gly Phe Trp Asp Trp Val Gly Gly Arg Tyr Ser Val Asp Ser Ala  
 260 265 270  
 Val Gly Leu Ser Leu Met Ala Val Ile Gly Pro Arg Asp Phe Met Arg  
 275 280 285  
 Phe Leu Gly Gly Phe His Ala Met Asp Glu His Phe Arg Thr Thr Lys  
 290 295 300  
 Phe Glu Glu Asn Val Pro Ile Leu Met Ala Leu Leu Gly Val Trp Tyr  
 305 310 315 320  
 Ser Asp Phe Tyr Gly Ala Glu Thr His Ala Val Leu Pro Tyr Ser Glu  
 325 330 335  
 Asp Leu Ser Arg Phe Ala Ala Tyr Leu Gln Gln Leu Thr Met Glu Ser  
 340 345 350  
 Asn Gly Lys Ser Val His Arg Asp Gly Ser Pro Val Ser Thr Gly Thr  
 355 360 365  
 Gly Glu Ile Tyr Trp Gly Glu Pro Gly Thr Asn Gly Gln His Ala Phe  
 370 375 380  
 Phe Gln Leu Ile His Gln Gly Thr Arg Leu Val Pro Ala Asp Phe Ile  
 385 390 395 400



Gly Phe Ala Arg Pro Lys Gln Asp Leu Pro Ala Gly Glu Arg Thr Met  
405 410 415

His Asp Leu Leu Met Ser Asn Phe Phe Ala Gln Thr Lys Val Leu Ala  
420 425 430

Phe Gly Lys Asn Ala Glu Glu Ile Ala Ala Glu Gly Val Ala Pro Glu  
435 440 445

Leu Val Asn His Lys Val Met Pro Gly Asn Arg Pro Thr Thr Thr Ile  
450 455 460

Leu Ala Glu Glu Leu Thr Pro Ser Ile Leu Gly Ala Leu Ile Ala Leu  
465 470 475 480

Tyr Glu His Ile Val Met Val Gln Gly Val Ile Trp Asp Ile Asn Ser  
485 490 495

Phe Asp Gln Trp Gly Val Glu Leu Gly Lys Gln Gln Ala Asn Asp Leu  
500 505 510

Ala Pro Ala Val Ser Gly Glu Glu Asp Val Asp Ser Gly Asp Ser Ser  
515 520 525

Thr Asp Ser Leu Ile Lys Trp Tyr Arg Ala Asn Arg  
530 535 540

<210> 3  
<211> 25  
<212> DNA  
<213> Corynebacterium glutamicum

<400> 3  
gctgatgtcc acgaagcttt gggac 25

<210> 4  
<211> 25  
<212> DNA  
<213> Corynebacterium glutamicum

<400> 4  
gctgagaacc ttggaataag gtagg 25